Breaking News, Collaborations & Alliances

Ablynx, AbbVie in Inflammatory Pact

To develop anti-IL-6R Nanobody in potential $835 million deal

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Ablynx and AbbVie have entered into a global license agreement to develop and commercialize ALX-0061, an anti-IL-6R Nanobody, to treat inflammatory diseases. ALX-0061 successfully completed a Phase IIa study in February 2013, reporting strong efficacy and safety data in patients with moderately to severely active rheumatoid arthritis (RA) on a stable background of methotrexate. Ablynx will be responsible for completing Phase II development in both RA and systemic lupus erythematosus (SLE). Upon...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters